Methods of diagnosing and treating stress urinary incontinence

• US 20040146894A1
• Filed: 10/14/2003
• Published: 07/29/2004
• Est. Priority Date: 10/14/2002
• Status: Abandoned Application

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.), Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Original Assignee: Affymetrix, Inc. (Thermo Fisher Scientific Incorporated)
• Inventors: Chen, Bertha, Warrington, Janet A., Polan, Mary Lake, Zhang, Zhaomei, Wen, Yan
• Application Number:
  US10/684,539
• Publication Number:
  US 20040146894A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The invention disclosed in this application provides methods of diagnosing and treating stress urinary incontinence and predisposition to stress urinary incontinence. These methods are based on the identification of significant differences in gene expression in the pelvic supporting tissues of premenopausal women afflicted with SUI as compared with continent, control women, using microarray-based techniques. The identified differences in gene expression may contribute to altered ECM metabolism and ECM remodeling in pelvic tissue from SUI women. The invention also provides candidate genes for use in diagnosing disorders characterized by pelvic floor dysfunction, including SUI, identification of therapeutic gene targets, evaluation of treatment regimens, prediction of treatment outcome, design of therapeutic agents, and identification of individuals at risk for developing these disorders. Various embodiments of the present invention are disclosed which relate to the above-described uses of candidate genes.

Claims

1. A method of diagnosing stress urinary incontinence or predisposition to stress urinary incontinence in a premenopausal subject comprising analyzing reproductive hormone-modulated gene expression in a pelvic supporting tissue of the subject and comparing the obtained results with a predetermined indicator of differential expression of said genes in SUI subjects relative to normal continent subjects.

2. The method of claim 1, wherein said tissue is obtained from the subject during the proliferative (estrogen only) phase of the menstrual cycle.

3. The method of claim 1, wherein said tissue is obtained from the subject during the secretory (estrogen+progesterone) phase of the menstrual cycle.

4. The method of claim 1, wherein the pelvic supporting tissue is selected from the group consisting of vaginal cuff tissue, periurethral vaginal wall tissue, vaginal epithelium, periuterine tissue and pelvic ligamentous tissue.

5. The method of claim 1, wherein gene expression is assessed by measuring the levels of gene transcription in said tissue sample.

6. The method of claim 5, wherein gene expression is measured by quantitative competitive PCR.

7. The method of claim 5, wherein gene expression is measured by hybridization of gene transcripts from said tissue to oligonucleotide probes.

8. The method of claim 1, wherein gene expression is analyzed using a nucleic acid array.

9. The method of claim 1, wherein the predetermined indicator comprises empirically determined differential gene expression values obtained by parallel measurements of SUI pelvic supporting tissues and matched tissues of normal controls.

10. The method of claim 1, wherein the predetermined indicator comprises a gene expression profile of the pelvic supporting tissue of the same subject determined at a time prior to the appearance of symptoms of pelvic floor dysfunction.

11. The method of claim 1, wherein gene expression is analyzed for one or more genes selected from the group consisting of genes involved in ECM metabolism, collagen degradation, elastin degradation and myocyte function.

12. The method of claim 8, wherein said array comprises one or more gene probes selected from the group consisting of elafin, IL-1RA, keratin 14, keratin 16, collagen type XVII, plakophilin, RAMP1, and alpha 1 antitrypsin.

13. The method of claim 8, wherein said array further comprises one or more gene probes selected from the group consisting of alpha 2 actin, actin depolymerizing factor, smooth muscle myosin, myosin light chain kinase, tropomyosin, tropomyosin 1, microfibril-associated glycoprotein-2, insulin-like growth factor binding protein 7 and collagen type IV alpha chain.

14. The method of claim 8, wherein said array comprises one or more gene probes selected from the group consisting of TGF-beta 3, laminin, collagen type VI, LIM protein, distryophin, laminin-related protein (LAMA3), collagen XVII (BP180), serine/threonine protein kinase, type II interleukin-1 receptor, PDGF-associated protein, matrix metalloproteinases, and alpha 1 antitrypsin.

15. A method for treating a premenopausal patient diagnosed as having urinary incontinence or predisposition to urinary incontinence, according to the method of claim 1, the method comprising reducing proteolysis of collagen and elastin in pelvic supporting tissue of the patient and determining the effect of the treatment on the patient'"'"'s condition.

16. The method of claim 15, wherein reducing proteolysis of collagen and elastin in pelvic supporting tissue is accomplished by administering to the patient an effective amount of one or more of the following:

(a) an elastase inhibitor;

(b) a metalloproteinase inhibitor;

(c) a modulator of elafin levels;

(d) a TIMP or a TIMP analog or derivative;

(e) a modulator of TIMP levels